E-mail: ClinicalTrials@ ImClone.com
Eli Lilly and Company
22
0
19
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+15 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (20)
Showing 10 of 20 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Tim F Greten, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
lin shen
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Mark Levine, MD
Ontario Clinical Oncology Group (OCOG)
Shared therapeutic areas:
Jeong Min Lee, MD
Seoul National University Hospital
Shared therapeutic areas:
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
You Lu, MD
West China Hospital
Shared therapeutic areas:
Francesco Perrone, M.D., Ph.D.
National Cancer Institute, Naples
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (22)
Showing 20 of 22 trials
Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer
Study of gp75 Vaccine in Patients With Stage III and IV Melanoma
Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma
A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer
Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer
Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer
A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy
Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer
Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy
A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma
Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available
Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy
A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available
Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before